With a clear conscience, I recommend OncoCDx services. The clients are very satisfied with the analysis performed on raw data generated by Macrogen - in simple as well as in very complex projects.
Genomic Profiling
for
Personalized Diagnostics
about us
Helping to bring forward the day when all cancers are curable
OncoCDx is a not for profit socially responsible research organization established by researchers from the top institutes and universities in the world, including University of Cambridge, UK, Oxford, UK and California Berkeley, USA.
We believe survival is the general human right no matter of the race, ethnicity, ability, nationality, wealth, and gender.
Our mission is to provide doctors with the most comprehensive equipment and patients with more personalized diagnostics.
Integrate knowledge
with comprehensive Genomic Profiling
for more PERSONALIZED diagnostics
From ‘One treatment fits all’
Since a long time diagnosed patient is treated in accordance with standardized protocol that is is nearly the same for every individual
Standard protocols mostly rely on comprehensive clinical trials engaging statistically significant number of patients. It allows to assess the percentage of cases where the medication is effective and when side effects may occur with higher probability.¹
¹ Sharma & Sethi, Standard Treatment Guidelines - A Manual for Medical Therapeutics 6th edition, 2021
To More personalized diagnostics
Personalized medicine is an emerging practice of medicine that uses an individual's genetic profile to guide decisions made in regard to the prevention, diagnosis, and treatment of disease
Personalized medicine is an opportunity to take a "one size fits all" approach to diagnostics and drug therapy and prevention and turn it into an individualized approach.
Knowledge of a patient's genetic profile can help doctors select the proper medication or therapy and administer it using the proper dose or regimen.
It also allows the possibility in some instances of picking the right drug at the right dose for the right person instead of the "one size fits all" approach to drug therapy.²
² Gambardella et al., Personalized Medicine: Recent Progress in Cancer Therapy, 2020
do you need a consultation?
Read more about the OncoCDx a companion diagnostics in cancer immunotherapy
Human leukocyte antigen (HLA) typing
HLA locus is involved in the mechanisms of tumor tolerance and diagnosis. The HLA class I and class II genotyping along with expression analysis are currently one of the most promising clinical approaches.
Neoantigens prediction and vaccines design
Tumour neoantigens are crucial for immune response to immunotherapy. Identification, scoring and indication neoantigens that induce the strongest immune response, excluding false positives ones is encouraging direction to design personalized cancer vaccines.
Somatic and germline mutations
Reliable identification of somatic and germline mutations is an essential element of cancer genome research and patients' molecular diagnostics.
Multilevel expression analysis
Integration of multiple sequencing technologies leveraged by machine learning technology increases statistical power to detect novel mutations, especially in low purity tumours.
Identification and characterization of functional lncRNAs
Long non-coding RNAs play a crucial role in regulatory biology. They can act as a regulatory factors essential for tumour and microbiome biology. We identify potential lncRNAs and apply machine learning to predict the effects of its mutations.
Molecular Modelling and Computational Biology
Molecular modelling encompasses all methods, theoretical and computational, used to model or mimic the behaviour of molecules. The methods are used in computational biology to study molecular systems ranging from small chemical systems to large biological molecules.
Computer Aided Drug Design (CADD)
Computer-aided drug design includes computational chemistry, molecular modelling, molecular design and rational drug design. Our original in-house tools and knowledge leaded to therapeutic molecules currently being under the last phase of clinical trial.
